WealthDefender 7 review

Yes, with qualifications. For someone who wants indexed accumulation, principal protection, and a modest built-in long-term-care-adjacent benefit without paying a rider fee, WealthDefender 7 is a reasonably built contract. It's a weaker fit for someone who wants guaranteed lifetime income — there isn't a rider at all, optional or otherwise — needs the money before year 7, or lives in one of the several states where it isn't currently approved.

Buyers pick this because there's no add-on fee to get index-linked growth with a locked floor after the surrender period, and because the death benefit is unusually clean: full contract value, no withdrawal charge, no MVA haircut, even inside the surrender window. The ADL/nursing-home/terminal-illness waiver is baked in at no extra cost in most states, functioning as free optionality for buyers worried about a health event forcing an early exit. For someone who already has income sources covered and just wants tax-deferred growth with a downside floor, this checks the boxes without adding rider costs to the equation.

This fits someone in their accumulation years — pre-retirement to early retirement — who has other income sources handled (Social Security, a pension, a separate income annuity) and is using this contract purely for tax-deferred growth and legacy planning. It's a reasonable fit inside a qualified or non-qualified account where the buyer can commit for 7 years. It's a poor fit for anyone who needs guaranteed lifetime income, anyone who might need more than 10% of the contract per year, and residents of Alabama, Florida, New Jersey, New York, South Carolina, Vermont, or Wisconsin, where it isn't approved.

You're not buying market exposure. You're buying an insurance contract that credits interest based on formulas tied to index performance — a 1-year point-to-point cap on the S&P 500, a 1-year or 2-year strategy on two lesser-known indices (the Nasdaq-100 Engle 10% Index and the Barclays Tactical Growth Index), or a plain fixed-rate account. None of these hand you the index's actual return; they hand you a formula-based credit, capped or scaled by a participation rate. In exchange, your principal is protected from index losses, and the guaranteed minimum surrender value puts a floor under the contract even in a worst case.

The crediting menu has three paths. The Fixed Interest Strategy just pays a declared rate — 4.30% under $100,000, 4.50% at $100,000 or more, as of the brochure's June 2025 rate snapshot — with no index involved. The Annual Point-to-Point strategies reset every year: the S&P 500 version uses a cap (8.25%/9.25% by premium band), while the Nasdaq-100 Engle and Barclays Tactical Growth versions use a participation rate (84% on both, at the 1-year term) instead of a cap. There's also a 2-Year Point-to-Point (Term End Point) option on the two secondary indices, crediting once every two years at a higher participation rate (116% and 121%) to reward the longer measurement period. After the initial term, cap and participation rates reset, but Ibexis guarantees they won't fall below 1.00% (cap) or 10% (participation) for the life of the contract — a real floor, not just a marketing footnote.

The second most important feature here isn't a rider at all — it's the combination of the death benefit and the chronic-illness waiver, both built in at no extra cost. The death benefit pays the full contract value to a beneficiary with no withdrawal charge and no MVA deduction, even during the surrender period, and a surviving spouse who is the sole beneficiary can continue the contract in their own name rather than cashing out. Separately — and not available in every state, including the California version — the contract waives withdrawal charges for ADLs, nursing home or hospital confinement, and terminal illness. That's not a substitute for long-term-care insurance, but it does mean a health event doesn't automatically trigger a surrender penalty on money you need.

You can take out 10% of contract value penalty-free each year starting after the first contract anniversary, and RMDs are treated as free withdrawals from year two onward even if they exceed that 10%. Anything beyond that during the first 7 years runs into the surrender schedule below, and — this is the part to watch — a market value adjustment can add to or subtract from that charge depending on where interest rates have moved since issue. A bailout provision offers some relief: if the renewal S&P 500 cap ever falls below Ibexis's declared bailout rate, you get a 30-day, penalty-free withdrawal window. You'll also need to keep at least $5,000 in the contract after any withdrawal, and withdrawals have a $1,000 minimum, so this isn't built for frequent small draws.

There's no disclosed annual contract fee, M&E charge, or administration fee — the available materials don't show one, and there's no income rider to carry a rider fee either. The real cost shows up in the crediting formulas themselves: caps and participation rates limit how much of an index's gain actually reaches you, and the two secondary indices (Nasdaq-100 Engle, Barclays Tactical Growth) are the kind of proprietary strategy indices that often carry embedded costs baked into how the index itself is calculated — costs that can quietly reduce what a cap or participation rate is applied to. None of that is unique to WealthDefender 7; it's standard for FIAs using this kind of index. But it's worth knowing you're trading some transparency for the no-fee structure.

Legal Entity: Ibexis Life & Annuity Insurance Company

A.M. Best Rating: A-